177 related articles for article (PubMed ID: 22136433)
21. Design, synthesis and in vitro and in vivo antitumor activities of novel bivalent β-carbolines.
Shi B; Cao R; Fan W; Guo L; Ma Q; Chen X; Zhang G; Qiu L; Song H
Eur J Med Chem; 2013 Feb; 60():10-22. PubMed ID: 23279863
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological activities of 4-substituted pyrrolo[2,3-a]carbazole Pim kinase inhibitors.
Giraud F; Akué-Gédu R; Nauton L; Candelon N; Debiton E; Théry V; Anizon F; Moreau P
Eur J Med Chem; 2012 Oct; 56():225-36. PubMed ID: 22982527
[TBL] [Abstract][Full Text] [Related]
23. A New Series of Antileukemic Agents: Design, Synthesis, In Vitro and In Silico Evaluation of Thiazole-Based ABL1 Kinase Inhibitors.
Zeytün E; Altıntop MD; Sever B; Özdemir A; Ellakwa DE; Ocak Z; Ciftci HI; Otsuka M; Fujita M; Radwan MO
Anticancer Agents Med Chem; 2021; 21(9):1099-1109. PubMed ID: 32838725
[TBL] [Abstract][Full Text] [Related]
24. Ethyl 2-(benzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine-6-carboxylate analogues as a new scaffold for protein kinase casein kinase 2 inhibitor.
Jin CH; Jun KY; Lee E; Kim S; Kwon Y; Kim K; Na Y
Bioorg Med Chem; 2014 Sep; 22(17):4553-65. PubMed ID: 25131958
[TBL] [Abstract][Full Text] [Related]
25. Biological evaluation and docking studies of recently identified inhibitors of phosphoinositide-3-kinases.
Sabbah DA; Simms NA; Brattain MG; Vennerstrom JL; Zhong H
Bioorg Med Chem Lett; 2012 Jan; 22(2):876-80. PubMed ID: 22212721
[TBL] [Abstract][Full Text] [Related]
26. Synthesis of 1-substituted carbazolyl-1,2,3,4-tetrahydro- and carbazolyl-3,4-dihydro-β-carboline analogs as potential antitumor agents.
Shen YC; Chang YT; Lin CL; Liaw CC; Kuo YH; Tu LC; Yeh SF; Chern JW
Mar Drugs; 2011 Feb; 9(2):256-277. PubMed ID: 21566798
[TBL] [Abstract][Full Text] [Related]
27. Structure-based design and SAR development of novel selective polo-like kinase 1 inhibitors having the tetrahydropteridin scaffold.
Lv X; Yang X; Zhan MM; Cao P; Zheng S; Peng R; Han J; Xie Z; Tu Z; Liao C
Eur J Med Chem; 2019 Dec; 184():111769. PubMed ID: 31629162
[TBL] [Abstract][Full Text] [Related]
28. Structure-based design of imidazo[1,2-a]pyrazine derivatives as selective inhibitors of Aurora-A kinase in cells.
Bouloc N; Large JM; Kosmopoulou M; Sun C; Faisal A; Matteucci M; Reynisson J; Brown N; Atrash B; Blagg J; McDonald E; Linardopoulos S; Bayliss R; Bavetsias V
Bioorg Med Chem Lett; 2010 Oct; 20(20):5988-93. PubMed ID: 20833547
[TBL] [Abstract][Full Text] [Related]
29. Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing.
Reader JC; Matthews TP; Klair S; Cheung KM; Scanlon J; Proisy N; Addison G; Ellard J; Piton N; Taylor S; Cherry M; Fisher M; Boxall K; Burns S; Walton MI; Westwood IM; Hayes A; Eve P; Valenti M; de Haven Brandon A; Box G; van Montfort RL; Williams DH; Aherne GW; Raynaud FI; Eccles SA; Garrett MD; Collins I
J Med Chem; 2011 Dec; 54(24):8328-42. PubMed ID: 22111927
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and antitumoral activity of novel 3-(2-substituted-1,3,4-oxadiazol-5-yl) and 3-(5-substituted-1,2,4-triazol-3-yl) beta-carboline derivatives.
Formagio AS; Tonin LT; Foglio MA; Madjarof C; de Carvalho JE; da Costa WF; Cardoso FP; Sarragiotto MH
Bioorg Med Chem; 2008 Nov; 16(22):9660-7. PubMed ID: 18951806
[TBL] [Abstract][Full Text] [Related]
31. Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology.
Boga SB; Alhassan AB; Cooper AB; Doll R; Shih NY; Shipps G; Deng Y; Zhu H; Nan Y; Sun R; Zhu L; Desai J; Patel M; Muppalla K; Gao X; Wang J; Yao X; Kelly J; Gudipati S; Paliwal S; Tsui HC; Wang T; Sherborne B; Xiao L; Hruza A; Buevich A; Zhang LK; Hesk D; Samatar AA; Carr D; Long B; Black S; Dayananth P; Windsor W; Kirschmeier P; Bishop R
Bioorg Med Chem Lett; 2018 Jun; 28(11):2029-2034. PubMed ID: 29748051
[TBL] [Abstract][Full Text] [Related]
32. Development of new fluorescent xanthines as kinase inhibitors.
Kim D; Jun H; Lee H; Hong SS; Hong S
Org Lett; 2010 Mar; 12(6):1212-5. PubMed ID: 20184370
[TBL] [Abstract][Full Text] [Related]
33. Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors.
Tao ZF; Wang L; Stewart KD; Chen Z; Gu W; Bui MH; Merta P; Zhang H; Kovar P; Johnson E; Park C; Judge R; Rosenberg S; Sowin T; Lin NH
J Med Chem; 2007 Apr; 50(7):1514-27. PubMed ID: 17352464
[TBL] [Abstract][Full Text] [Related]
34. 2-Thioxothiazolidin-4-one Analogs as Pan-PIM Kinase Inhibitors.
Yun Y; Hong VS; Jeong S; Choo H; Kim S; Lee J
Chem Pharm Bull (Tokyo); 2021; 69(9):854-861. PubMed ID: 34470949
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one-based potent and selective Chk-1 inhibitors.
Wang L; Sullivan GM; Hexamer LA; Hasvold LA; Thalji R; Przytulinska M; Tao ZF; Li G; Chen Z; Xiao Z; Gu WZ; Xue J; Bui MH; Merta P; Kovar P; Bouska JJ; Zhang H; Park C; Stewart KD; Sham HL; Sowin TJ; Rosenberg SH; Lin NH
J Med Chem; 2007 Aug; 50(17):4162-76. PubMed ID: 17658776
[TBL] [Abstract][Full Text] [Related]
36. Discovery of DB18, a potent inhibitor of CLK kinases with a high selectivity against DYRK1A kinase.
Brahmaiah D; Kanaka Durga Bhavani A; Aparna P; Sampath Kumar N; Solhi H; Le Guevel R; Baratte B; Ruchaud S; Bach S; Singh Jadav S; Raji Reddy C; Roisnel T; Mosset P; Levoin N; Grée R
Bioorg Med Chem; 2021 Feb; 31():115962. PubMed ID: 33422908
[TBL] [Abstract][Full Text] [Related]
37. Structure-based design and synthesis of novel pseudosaccharine derivatives as antiproliferative agents and kinase inhibitors.
Elsayed MS; El-Araby ME; Serya RA; El-Khatib AH; Linscheid MW; Abouzid KA
Eur J Med Chem; 2013 Mar; 61():122-31. PubMed ID: 23063746
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and molecular modeling studies of new series of antitumor 1,2,4-triazines with potential c-Met kinase inhibitory activity.
El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
Bioorg Chem; 2018 Feb; 76():154-165. PubMed ID: 29175587
[TBL] [Abstract][Full Text] [Related]
39. Design of beta-carboline derivatives as DNA-targeting antitumor agents.
Guan H; Chen H; Peng W; Ma Y; Cao R; Liu X; Xu A
Eur J Med Chem; 2006 Oct; 41(10):1167-79. PubMed ID: 16790297
[TBL] [Abstract][Full Text] [Related]
40. Scaffold Repurposing of In-House Small Molecule Candidates Leads to Discovery of First-in-Class CDK-1/HER-2 Dual Inhibitors: In Vitro and In Silico Screening.
Elkamhawy A; Ammar UM; Paik S; Abdellattif MH; Elsherbeny MH; Lee K; Roh EJ
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]